Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355098 | 0.90 | POLB (0.53) | LTA4HEPHX2KDM4EPOLBACACB | |
| SCHEMBL11683841 | 0.89 | POLB (0.51) | LTA4HEPHX2KDM4EPOLBACACB | |
| SCHEMBL23266258 | 0.85 | POLB (0.51) | LTA4HEPHX2KDM4EPOLBACACB | |
| SCHEMBL4508064 | 0.84 | SIGMAR1 (0.47) | LTA4HEPHX2SIGMAR1BCHEKDM4E | |
| SCHEMBL9112221 | 0.83 | POLB (0.50) | LTA4HEPHX2KDM4EPOLBACACB | |
| SCHEMBL9027085 | 0.83 | POLB (0.50) | LTA4HEPHX2KDM4EPOLBACACB | |
| SCHEMBL5174164 | 0.82 | BCHE (0.47) | BCHEKDM4EPOLBLMNAL3MBTL1 | |
| SCHEMBL14033258 | 0.82 | LTA4H (0.73) | LTA4HEPHX2SIGMAR1FFAR1PPARA | |
| SCHEMBL29886710 | 0.82 | LTA4H (0.73) | LTA4HEPHX2BCHEPOLBFFAR1 | |
| SCHEMBL3172997 | 0.82 | APP (0.59) | BCHEPOLBPPARALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527065-B1 | METHOD FOR THE PRODUCTION OF (S)-3-METHYLAMINO-1-(THIEN-2-YL)PROPAN-1-OL | BASF AG (DE) | 2006-11-22 | — | — | EP | claimed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7435563-B2 | Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | BAYER HEALTHCARE AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1740540-A1 | PHENYL ACETAMIDES | Bayer HealthCare AG (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2005103001-A1 | PHENYL ACETAMIDES | BAYER HEALTHCARE AG (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050245749-A1 | Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-03 | — | — | US | disclosed |
| EP-1572628-A1 | ISOPHTALIC ACID DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052839-A1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176898-A1 | Leukotriene antagonists; cardiovascular disorders like unstable angina pectoris or myocardial infarction; Methyl 1-{[5-(ethoxycarbonyl)-2-(3-{4-[(4-isopropoxybenzyl)oxy]phenyl}propoxy)phenyl]-acetyl}piperidine-4-carboxylate | LTC4S, LTB4R2, LTB4R | LTA4H 6/4885EPHX2 1210/4885SIGMAR1 2420/4885 |
| US-20050245749-A1 | Method for the production of (s)-3-methylamino-1-(thien-2-yl)propan-1-ol | INMT, PNMT, TH | LTA4H 2271/4885EPHX2 692/4885SIGMAR1 572/4885 |
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | LTA4H 281/4885EPHX2 214/4885SIGMAR1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.